Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models

Program in Integrative Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Free Radical Biology and Medicine (Impact Factor: 5.71). 05/2011; 51(3):681-7. DOI: 10.1016/j.freeradbiomed.2011.05.031
Source: PubMed

ABSTRACT Two popular complementary, alternative, and integrative medicine therapies, high-dose intravenous ascorbic acid (AA) and intravenous glutathione (GSH), are often coadministered to cancer patients with unclear efficacy and drug-drug interaction. In this study we provide the first survey evidence for clinical use of iv GSH with iv AA. To address questions of efficacy and drug-drug interaction, we tested 10 cancer cell lines with AA, GSH, and their combination. The results showed that pharmacologic AA induced cytotoxicity in all tested cancer cells, with IC(50) less than 4 mM, a concentration easily achievable in humans. GSH reduced cytotoxicity by 10-95% by attenuating AA-induced H(2)O(2) production. Treatment in mouse pancreatic cancer xenografts showed that intraperitoneal AA at 4 g/kg daily reduced tumor volume by 42%. Addition of intraperitoneal GSH inhibited the AA-induced tumor volume reduction. Although all treatments (AA, GSH, and AA+GSH) improved survival rate, AA+GSH inhibited the cytotoxic effect of AA alone and failed to provide further survival benefit. These data confirm the pro-oxidative anti-cancer mechanism of pharmacologic AA and suggest that AA and GSH administered together provide no additional benefit compared with AA alone. There is an antagonism between ascorbate and glutathione in treating cancer, and therefore iv AA and iv GSH should not be coadministered to cancer patients on the same day.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ascorbic acid (AA) is capable to inhibit cancer cell growth by perturbing normal redox state of cells and causing toxic effects through the generation of abundant reactive oxygen species (ROS). However, the clinical utility of AA at tolerable dosage is plagued by relatively low in vivo efficacy. This study describes the development of a peroxidase-like composite nanoparticle for use in an AA-mediated therapeutic strategy. Based on a high-throughput, one-pot solvothermal approach, Fe3O4@C nanoparticles (NPs) are synthesized and then modified with folic acid (FA) on the surface. Particular focus is then concentrated on the assessment of peroxidase-like catalytic activity by a chromogenic reaction in the presence of H2O2. The carbon shell of Fe3O4@C NPs is proved to have partially graphitized carbon and thus facilitates electron transfer in the catalytic decomposition of H2O2 leading to the production of highly reactive hydroxyl radicals. Along with magnetic responsiveness and receptor-binding specificity, intrinsic peroxidase-like catalytic activity of Fe3O4@C-FA NPs pronouncedly promote the AA-induced oxidative stress of cancer cells and optimize the ROS-mediated antineoplastic efficacy of exogenous AA. In vitro experiments for human prostate cancer PC-3 cells demonstrate that Fe3O4@C-FA NPs serve as peroxidase mimic to create hydroxyl radicals from the source of endogenous H2O2 that is yielded by exogenous AA via an oxidative stress process. The usage of dual agent leads to the largely enhanced cytotoxicity to PC-3 cells, and, due to synergistic effect of NPs, the administrated dosage of AA is reduced markedly. On the other hand, since normal cells (HEK 293T cells) appear to have a higher capacity to cope with additionally generated ROS than cancer cells do, the NP-AA couple shows little damage in this case, proving that selective killing of cancer cells could be achieved owing to preferential accumulation of ROS in cancer cells. Then a possible ROS-mediated mechanism is discussed to elucidate the pharmaceutical profile of NP-AA agent. In general, this foundational study corroborates that the peroxidase-like nanomaterials are applicable to modulate the oxidative stress for selective treatment of cancer cells by a high level of endogenous ROS.
    ACS Applied Materials & Interfaces 11/2013; 5(24). DOI:10.1021/am4042367 · 5.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ascorbic acid (AA) exhibits significant anticancer activity at pharmacologic doses achievable by parenteral administration that have minimal effects on normal cells. Thus, AA has potential uses as a chemotherapeutic agent alone or in combination with other therapeutics that specifically target cancer-cell metabolism. We compared the effects of AA and combinations of AA with the glycolysis inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3-PO) on the viability of three non-small cell lung cancer (NSCLC) cell lines to the effects on an immortalized lung epithelial cell line. AA concentrations of 0.5 to 5 mM caused a complete loss of viability in all NSCLC lines compared to a <10% loss of viability in the lung epithelial cell line. Combinations of AA and 3-PO synergistically enhanced cell death in all NSCLC cell lines at concentrations well below the IC50 concentrations for each compound alone. A synergistic interaction was not observed in combination treatments of lung epithelial cells and combination treatments that caused a complete loss of viability in NSCLC cells had modest effects on normal lung cell viability and reactive oxygen species (ROS) levels. Combination treatments induced dramatically higher ROS levels compared to treatment with AA and 3-PO alone in NSCLC cells and combination-induced cell death was inhibited by addition of catalase to the medium. Analyses of DNA fragmentation, poly (ADP-ribose) polymerase cleavage, annexin V-binding, and caspase activity demonstrated that AA-induced cell death is caused via the activation of apoptosis and that the combination treatments caused a synergistic induction of apoptosis. These results demonstrate the effectiveness of AA against NSCLC cells and that combinations of AA with 3-PO synergistically induce apoptosis via a ROS-dependent mechanism. These results support further evaluation of pharmacologic concentrations of AA as an adjuvant treatment for NSCLC and that combination of AA with glycolysis inhibitors may be a promising therapy for the treatment of NSCLC.
    PLoS ONE 06/2013; 8(6):e67081. DOI:10.1371/journal.pone.0067081 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of vitamin C (ascorbate) in cancer prevention, tumor growth, and treatment is of intense public interest. Clinical trial data have been sparse, contradictory, and highly controversial, and robust pre-clinical data are required for progress. This paper reviews pre-clinical models and their limitations with respect to ascorbate research. Most studies have utilized animals able to synthesize ascorbate and thus are not ideal models of the human condition. More recently, genetically modified mouse models have become available; yet, all studies compared healthy and scorbutic mice. The majority of investigations to date concluded that increased ascorbate led to decreased tumor growth, but data on mechanisms and doses are inconclusive. Clinically relevant animal studies are still required to convince a generally sceptical medical audience of the potential worth of ascorbate as an adjunct to therapy.
    Frontiers in Oncology 10/2014; 4:282. DOI:10.3389/fonc.2014.00282


Available from
May 30, 2014